HAP Trading’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-281
Closed -$6K 2442
2022
Q1
$6K Sell
281
-141
-33% -$57.9K ﹤0.01% 1918
2021
Q4
$24K Sell
422
-72
-15% -$36.2K ﹤0.01% 1741
2021
Q3
$21K Sell
494
-178
-26% -$89.3K ﹤0.01% 1797
2021
Q2
$47K Buy
+672
New +$426K ﹤0.01% 1499
2021
Q1
Sell
-333
Closed -$9K 2657
2020
Q4
$9K Sell
333
-39
-10% -$20.4K ﹤0.01% 1932
2020
Q3
$4K Buy
+372
New +$216K ﹤0.01% 1471
2020
Q2
Sell
-572
Closed -$16K 1884
2020
Q1
$16K Buy
572
+241
+73% +$131K ﹤0.01% 965
2019
Q4
$18K Buy
+331
New +$232K ﹤0.01% 910
2017
Q3
Sell
-325
Closed -$11K 1116
2017
Q2
$11K Sell
325
-86
-21% -$54.6K ﹤0.01% 840
2017
Q1
$37K Buy
+411
New +$220K ﹤0.01% 732

Other funds holding TVRD

HAP Trading's TVRD Position: Q2 2021 in Review

HAP Trading sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 425 shares — an estimated $269K sold.

HAP Trading first reported a position in TVRD in Q3 2018 and held it in 2 quarters. The position peaked at $332K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • HAP Trading reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HAP Trading sold 425 Tvardi Therapeutics shares in Q2 2021, an estimated $269K.
  • HAP Trading first reported a position in Tvardi Therapeutics in Q3 2018 and held it in 2 quarters.
  • HAP Trading's Tvardi Therapeutics position peaked at $332K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on HAP Trading's 13F filing for Q2 2021, filed 11 Aug 2021.